Pvs230D1-EPA

Pvs230D1-EPA is a transmission-blocking vaccine (TBV) candidate specifically designed to combat *Plasmodium vivax* malaria. It is a conjugate vaccine consisting of the recombinant Domain 1 of the Pvs230 protein—a gametocyte surface protein essential for the parasite's development within the mosquito—chemically linked to a carrier protein, *Pseudomonas aeruginosa* Exoprotein A (EPA), to enhance its immunogenicity. The vaccine does not protect the vaccinated individual from clinical malaria infection; instead, it induces specific antibodies that, when ingested by an *Anopheles* mosquito during a blood meal, bind to the Pvs230 protein on the parasites within the mosquito's midgut. This binding prevents the parasite from successfully completing its sexual life cycle and developing into oocysts, thereby halting the transmission of malaria to other humans. Developed primarily by the National Institute of Allergy and Infectious Diseases (NIAID), Pvs230D1-EPA is typically evaluated in clinical trials using intramuscular administration in combination with an adjuvant, such as Matrix-M, to maximize the functional antibody response.

Other names

Pvs230D1-rEPAPvs-230D1-rEPAPvs 230D1-rEPAPvs230D1MPvs-230D1MPvs 230D1MPlasmodium vivax transmission-blocking vaccine